JPRN UMIN000003055 2010.

Methods	Historically controlled trial Participants were not receiving lipid altering medications within 4 weeks of the study no washout required
Participants	Male and Female 20‐80 years old with NASH/NAFLD Included criteria: 1)The patients with fatty liver 2)The patients with the level of ALT (42‐120IU/L) 3)The patients with high cholesterol levels Exclusion criteria: 1)The patients with the use of drugs for dyslipidaemia within 4 weeks 2)The patients with chronic kidney disease (serum Cre>2.0) or severe liver dysfunction 3)The patients who are pregnant or giving the breast to a baby or want to be pregnant within the period of trial 4)The patients with cyclosporin 5)The patients with liver dysfunction by drug, alcohol, virus, or autoimmune factors
Interventions	pitavastatin calcium
Outcomes	The level of alanine aminotransferase
Notes	treatment period not reported

ALT: Alanine aminotransferase

CK: Creatine kinase

Cre: Creatinine

ECG: electrocardiogram

GPT: Glutamic‐pyruvic transaminase

HDL‐C: High density lipoprotein cholesterol

HMG‐CoA: 3‐hydroxy‐3‐methylglutaryl coenzyme A

IU: International unit

LDL‐C: Low density lipoprotein cholesterol

MB: Myocardial band

NAFLD: Nonalcohol fatty liver disease

NASH: Nonalcohol steatohepatitis

NYHA: New York Heart Association

PCI: Percutaneous coronary intervention

ST: End of S and start of T wave between ventricular depolarisation and repolarization electrocardiogram

TC: Total cholesterol

TG: Triglycerides